Clinical Trial

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-10-30; most recent amendment 2025-06-29.
Trial Details
NCT Number NCT06669117
Lead Sponsor Pierre Fabre Medicament
Conditions Solid Tumor, MET Alteration
Enrollment 140 participants
Start Date 2024-10-22
Primary Completion 2030-10-21 (estimated)
Study Completion 2032-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-02